The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.
The companies have agreed to distribute and codevelop diagnostics for the transplant monitoring market.
Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.
The company said it intends to use the proceeds for working capital and corporate purposes, including capital expenditures, R&D, clinical trials, and more.
Dendritics develops antibodies against immune system and other cells for the discovery of targets with high diagnostic, prognostic, and therapeutic potential.
The company outlined its plans to launch a kidney transplant rejection test that is based on cell-free DNA in 2019 and described its progress in breast cancer research.
Milwaukee, Wis.-based TAI Diagnostics is developing a PCR-based assay for cell-free DNA as a way to monitor the health of transplanted organs.
The firm's transplant allograft status test identifies genetic biomarkers that predict the likelihood of a patient's immune system to reject the organ over time.
Piper Jaffray analyst William Quirk said the pricing, which was much higher than expected, will help push CareDx toward profitability.
The final LCD covers AlloSure in renal allograft recipients who have a probability of active renal allograft rejection.